Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2025 pubmed 3 citations

Porphyromonas gingivalis outer membrane vesicles divert host innate immunity and promote inflammation via C4' monophosphorylated lipid A.

Coats. Stephen R SR; Su. Thet Hnin TH; Luderman Miller. Zoe Z; King. Alisa J AJ; Ortiz. Joshua J; Reddy. Angel A; Alaei. Sarah R SR; Jain. Sumita S

Key Findings

  • -monophosphorylated lipid A that strongly activates TLR4‑TRIF‑IFNβ and inflammasome‑IL‑1β pathways.",
  • , "Wild‑type Pg with non‑phosphorylated lipid A resists LL‑37 killing, while a ΔlpxF mutant with C4

Practical Outcomes

  • Boosting LL‑37 levels or using LL‑37‑like compounds might reduce gum‑disease‑driven inflammation, but they won’t eliminate the bacteria itself. Strategies that block the vesicle lipid or its interaction with TLR4 could be more effective for controlling periodontal and related systemic inflammation.

Summary

The gum‑disease bug Porphyromonas gingivalis releases tiny vesicles packed with a special lipid (C4'-MPLA) that fires up immune receptors and causes inflammation. The human antimicrobial peptide LL‑37 can block this inflammatory signaling, but it doesn’t kill the bacteria unless the bacteria’s lipid is altered. So LL‑37 may help calm gum‑related inflammation but isn’t a direct antibacterial cure.

Abstract

Porphyromonas gingivalis (Pg) is a prevalent pathogen that promotes human periodontal disease (PD) and exacerbates systemic comorbidities such as atherosclerosis, rheumatoid arthritis, and Alzheimer's disease. Pg produces nonphosphorylated tetra-acylated lipid A (NPLA) in its outer membrane (OM) that evades host Toll-like receptor 4 (TLR4), inflammasome pathways, and cationic peptides, enhancing bacterial survival. Here, we show that Pg also releases outer membrane vesicles (OMVs) that engage and divert host cell TLR4, inflammasome, and LL-37 responses away from the microbe. We determined that Pg OMVs are enriched for C4' monophosphoryl lipid A (C4'-MPLA), an established agonist for TLR4-TRIF-IFNβ and inflammasome-IL-1β responses. Comparisons of Pg 381 and Pg 33277 stationary phase cultures revealed higher OMV production by Pg 381, which correlates with its higher proinflammatory pathogenicity. The cationic peptide, polymyxin B (PMB), which selectively binds lipid A C4'-phosphate, reduces OMV-stimulated HEK cell TLR4 activation and THP-1 cell IL-1β production, confirming the proinflammatory role for OMV-C4'-MPLA. Similar to PMB, the host defense peptide, LL-37, inhibits OMV-C4'-MPLA-dependent HEK cell TLR4 activation. PMB and LL-37 also blocked OMV-C4'-MPLA-driven TLR4 activation in human umbilical vein endothelial cells. Finally, wild-type Pg-containing OM-NPLA is highly resistant to LL-37 antimicrobial activity, whereas the ΔlpxF mutant bacterium, retaining OM-C4'-MPLA, is killed by the peptide. In summary, Pg escapes host TLR4 signaling, inflammasome activation, and LL-37 interaction by retaining immunoevasive OM-NPLA. Moreover, Pg dispenses proinflammatory OMV-C4'-MPLA, which engages and redirects those host defenses. We suggest that OMV-C4'-MPLA triggers elevated IFNβ and IL-1β cytokines, which typify PD comorbidities, and drive PD-related alveolar bone loss.

Study Information

Provider

pubmed

Year

2025

Date

2025-05-01T00:00:00.000Z

DOI

10.1093/jimmun/vkae050

Citations

3

References

68